Macrophage Migration Inhibitory Factor as a Predictor for Long-term Improvements After Mindfulness-Based Group Therapy or Treatment as Usual for Depression, Anxiety or Stress and Adjustment Disorders
Sundquist, Kristina LU ; Palmér, Karolina LU ; Memon, Ashfaque A. LU
; Sundquist, Jan
LU
and Wang, Xiao
LU
(2020)
In Mindfulness
11(6).
p.1370-1377
- Abstract
Objectives: Identification of biological markers that can guide treatment selection is considered to be a viable solution for personalized treatment for patients with psychiatric disorders. This study investigated whether macrophage migration inhibitory factor (MIF) levels at baseline were associated with mindfulness-based group therapy or cognitive behavioral therapy response in patients with mild to moderate symptoms of depression, anxiety, or stress- and adjustment disorders. Methods: A total of 168 patients (aged 21–65 years) with psychiatric disorders were included from a randomized controlled trial. Plasma MIF levels in all the patients were analyzed using Luminex assay. Results: Higher MIF levels at baseline were significantly... (More)
Objectives: Identification of biological markers that can guide treatment selection is considered to be a viable solution for personalized treatment for patients with psychiatric disorders. This study investigated whether macrophage migration inhibitory factor (MIF) levels at baseline were associated with mindfulness-based group therapy or cognitive behavioral therapy response in patients with mild to moderate symptoms of depression, anxiety, or stress- and adjustment disorders. Methods: A total of 168 patients (aged 21–65 years) with psychiatric disorders were included from a randomized controlled trial. Plasma MIF levels in all the patients were analyzed using Luminex assay. Results: Higher MIF levels at baseline were significantly associated with better long-term (1-year follow-up) improvement in psychiatric symptoms, as measured by changes in the Montgomery-Åsberg Depression Rating Scale (MADRS-S), compared with lower MIF levels, after adjustment for baseline MADRS-S score, age, sex, BMI, and pharmacotherapy (β = 5.89, p = 0.001). Patients with higher levels of MIF (8235–23,391 pg/ml) had an almost 6 points’ larger decrease in MADRS-S score after 1 year compared with those with lower MIF (727–8223 pg/ml) at baseline. Similar trends were seen after 8 weeks, albeit non-significant (β = 1.99, p = 0.18). Conclusions: The findings indicate that higher plasma MIF levels at baseline may predict better long-term outcomes with psychotherapeutic interventions for mild to moderate symptoms of depression, anxiety, or stress and adjustment disorders. MIF levels may serve as a potential biomarker that can guide treatment selection for the personalized treatment for patients with psychiatric disorders.
(Less)
- author
- Sundquist, Kristina
LU
; Palmér, Karolina
LU
; Memon, Ashfaque A.
LU
; Sundquist, Jan
LU
and Wang, Xiao
LU
- organization
- publishing date
- 2020-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Anxiety, Cognitive behavioral therapy, Depression, Macrophage migration inhibitory factor, Mindfulness-based therapy
- in
- Mindfulness
- volume
- 11
- issue
- 6
- pages
- 8 pages
- publisher
- Springer
- external identifiers
-
- scopus:85082676443
- ISSN
- 1868-8527
- DOI
- 10.1007/s12671-020-01352-3
- language
- English
- LU publication?
- yes
- id
- 6539600a-b75f-4d0b-86d6-227051b66ed8
- date added to LUP
- 2020-04-13 12:53:04
- date last changed
- 2022-04-18 21:56:14
@article{6539600a-b75f-4d0b-86d6-227051b66ed8,
abstract = {{<p>Objectives: Identification of biological markers that can guide treatment selection is considered to be a viable solution for personalized treatment for patients with psychiatric disorders. This study investigated whether macrophage migration inhibitory factor (MIF) levels at baseline were associated with mindfulness-based group therapy or cognitive behavioral therapy response in patients with mild to moderate symptoms of depression, anxiety, or stress- and adjustment disorders. Methods: A total of 168 patients (aged 21–65 years) with psychiatric disorders were included from a randomized controlled trial. Plasma MIF levels in all the patients were analyzed using Luminex assay. Results: Higher MIF levels at baseline were significantly associated with better long-term (1-year follow-up) improvement in psychiatric symptoms, as measured by changes in the Montgomery-Åsberg Depression Rating Scale (MADRS-S), compared with lower MIF levels, after adjustment for baseline MADRS-S score, age, sex, BMI, and pharmacotherapy (β = 5.89, p = 0.001). Patients with higher levels of MIF (8235–23,391 pg/ml) had an almost 6 points’ larger decrease in MADRS-S score after 1 year compared with those with lower MIF (727–8223 pg/ml) at baseline. Similar trends were seen after 8 weeks, albeit non-significant (β = 1.99, p = 0.18). Conclusions: The findings indicate that higher plasma MIF levels at baseline may predict better long-term outcomes with psychotherapeutic interventions for mild to moderate symptoms of depression, anxiety, or stress and adjustment disorders. MIF levels may serve as a potential biomarker that can guide treatment selection for the personalized treatment for patients with psychiatric disorders.</p>}},
author = {{Sundquist, Kristina and Palmér, Karolina and Memon, Ashfaque A. and Sundquist, Jan and Wang, Xiao}},
issn = {{1868-8527}},
keywords = {{Anxiety; Cognitive behavioral therapy; Depression; Macrophage migration inhibitory factor; Mindfulness-based therapy}},
language = {{eng}},
number = {{6}},
pages = {{1370--1377}},
publisher = {{Springer}},
series = {{Mindfulness}},
title = {{Macrophage Migration Inhibitory Factor as a Predictor for Long-term Improvements After Mindfulness-Based Group Therapy or Treatment as Usual for Depression, Anxiety or Stress and Adjustment Disorders}},
url = {{http://dx.doi.org/10.1007/s12671-020-01352-3}},
doi = {{10.1007/s12671-020-01352-3}},
volume = {{11}},
year = {{2020}},
}